Literature DB >> 8625037

Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation.

Y Cao1, U R Karsten, W Liebrich, W Haensch, G F Springer, P M Schlag.   

Abstract

BACKGROUND: Expression of the pancarcinoma Thomsen-Friedenreich (TF) carbohydrate antigen or, more correctly, hapten, in colorectal carcinomas is not generally agreed on. Furthermore, its suggested role in liver metastasis so far has not been substantiated by direct immunohistochemical evidence.
METHODS: Cryostat sections from 52 primary tumors (20 with adjacent transitional mucosa), 22 liver metastases of colorectal carcinomas, and 17 samples of normal mucosae were examined immunohistologically with a panel of at least two monoclonal antibodies (mAbs) each to TF, to its precursor, Tn, and to sialosyl-Tn, among them two newly developed anti-TF mAbs.
RESULTS: Of the primary colorectal carcinomas, 60% expressed TF. Staining was more intense with TF-alpha/beta-reactive than with exclusively TF-alpha- or TF-beta-reactive mAbs. Normal and transitional mucosae were negative. Liver metastases were positive for TF in a significantly higher percentage of cases (91%) than primary carcinomas. Patients with TF-positive primary tumors had a significantly higher risk to develop liver metastases compared with patients with TF-negative tumors (57% vs. 14%, respectively). Tn and sialosyl-Tn were expressed concomitantly in most primary (85%) and metastatic (95%) colorectal carcinomas. These antigens also were detected in transitional mucosae (Tn in 25%, sialosyl-Tn in 55% of cases). Normal mucosae were negative.
CONCLUSIONS: These results prove unequivocally the presence of exposed TF epitopes in a majority of colorectal carcinomas in which both anomers of TF are expressed. These data further suggest that TF favors liver metastasis and that its expression in primary colorectal carcinomas is a significant risk factor for the development of liver metastasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8625037     DOI: 10.1002/1097-0142(19951115)76:10<1700::aid-cncr2820761005>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Correlation between the sialylation of cell surface Thomsen-Friedenreich antigen and the metastatic potential of colon carcinoma cells in a mouse model.

Authors:  Y Nemoto-Sasaki; M Mitsuki; M Morimoto-Tomita; A Maeda; M Tsuiji; T Irimura
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

2.  Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.

Authors:  Wei-Ming Lin; Uwe Karsten; Steffen Goletz; Ruo-Chuan Cheng; Yi Cao
Journal:  Int J Exp Pathol       Date:  2010-11-11       Impact factor: 1.925

Review 3.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 4.  Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision.

Authors:  María V Croce; Marina Isla-Larrain; Martín E Rabassa; Sandra Demichelis; Andrea G Colussi; Marina Crespo; Ezequiel Lacunza; Amada Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

5.  Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines.

Authors:  Qian Li; Miriam R Anver; Donna O Butcher; Jeffrey C Gildersleeve
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

6.  Tumor recognition of peanut agglutinin-immobilized fluorescent nanospheres in biopsied human tissues.

Authors:  Hironori Kumagai; Kosuke Yamada; Kanako Nakai; Tokio Kitamura; Kohta Mohri; Masami Ukawa; Takumi Tomono; Takaaki Eguchi; Testuya Yoshizaki; Takumi Fukuchi; Takuya Yoshino; Minoru Matsuura; Etsuo Tobita; Wellington Pham; Hiroshi Nakase; Shinji Sakuma
Journal:  Eur J Pharm Biopharm       Date:  2019-01-09       Impact factor: 5.571

7.  Sialylation of Thomsen-Friedenreich antigen is a noninvasive blood-based biomarker for GNE myopathy.

Authors:  Petcharat Leoyklang; May Christine Malicdan; Tal Yardeni; Frank Celeste; Carla Ciccone; Xueli Li; Rong Jiang; William A Gahl; Nuria Carrillo-Carrasco; Miao He; Marjan Huizing
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

8.  Carbohydrate expression profile of colorectal cancer cells is relevant to metastatic pattern and prognosis.

Authors:  Akira Konno; Yutaka Hoshino; Shinya Terashima; Ryoichi Motoki; Takanori Kawaguchi
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

9.  Multifunctional nanobeacon for imaging Thomsen-Friedenreich antigen-associated colorectal cancer.

Authors:  Hironori Kumagai; Wellington Pham; Makoto Kataoka; Ken-Ichiro Hiwatari; James McBride; Kevin J Wilson; Hiroyuki Tachikawa; Ryoji Kimura; Kunio Nakamura; Eric H Liu; John C Gore; Shinji Sakuma
Journal:  Int J Cancer       Date:  2012-10-30       Impact factor: 7.396

Review 10.  The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression.

Authors:  Lu-Gang Yu
Journal:  Glycoconj J       Date:  2007-04-25       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.